

# Bertram L Jacobs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6955249/publications.pdf>

Version: 2024-02-01

63  
papers

3,952  
citations

126858

33  
h-index

128225

60  
g-index

66  
all docs

66  
docs citations

66  
times ranked

3017  
citing authors

#	ARTICLE	IF	CITATIONS
1	Small Hero with Great Powers: Vaccinia Virus E3 Protein and Evasion of the Type I IFN Response. <i>Biomedicines</i> , 2022, 10, 235.	1.4	15
2	Detecting Necroptosis in Virus-Infected Cells. <i>Methods in Molecular Biology</i> , 2021, 2225, 199-216.	0.4	3
3	Optimization of translation enhancing element use to increase protein expression in a vaccinia virus system. <i>Journal of General Virology</i> , 2021, 102, .	1.3	1
4	Vaccinia virus E3 prevents sensing of Z-RNA to block ZBP1-dependent necroptosis. <i>Cell Host and Microbe</i> , 2021, 29, 1266-1276.e5.	5.1	66
5	Convergent Loss of the Necroptosis Pathway in Disparate Mammalian Lineages Shapes Viruses Countermeasures. <i>Frontiers in Immunology</i> , 2021, 12, 747737.	2.2	14
6	Subversion of Programed Cell Death by Poxviruses. <i>Current Topics in Microbiology and Immunology</i> , 2020, , 105-131.	0.7	4
7	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. <i>Journal of Virology</i> , 2019, 93, .	1.5	25
8	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. <i>Journal of Virology</i> , 2019, 93, .	1.5	13
9	Promoting Protein Translation in a Vaccinia Virus System Using Translation Enhancing Elements. <i>FASEB Journal</i> , 2018, 32, 651.11.	0.2	0
10	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	1.5	26
11	A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. <i>Virology</i> , 2017, 507, 242-256.	1.1	5
12	Inhibition of DAI-dependent necroptosis by the Z-DNA binding domain of the vaccinia virus innate immune evasion protein, E3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 11506-11511.	3.3	121
13	Characterization of a PKR inhibitor from the pathogenic ranavirus, <i>Ambystoma tigrinum</i> virus, using a heterologous vaccinia virus system. <i>Virology</i> , 2017, 511, 290-299.	1.1	6
14	Monkeypox virus induces the synthesis of less dsRNA than vaccinia virus, and is more resistant to the anti-poxvirus drug, IBT, than vaccinia virus. <i>Virology</i> , 2016, 497, 125-135.	1.1	29
15	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. <i>Journal of Virology</i> , 2016, 90, 4133-4149.	1.5	22
16	Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques. <i>PLoS ONE</i> , 2016, 11, e0153484.	1.1	20
17	Evasion of the Innate Immune Type I Interferon System by Monkeypox Virus. <i>Journal of Virology</i> , 2015, 89, 10489-10499.	1.5	57
18	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8525-8539.	1.5	35

#	ARTICLE	IF	CITATIONS
19	Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. <i>Journal of Virology</i> , 2015, 89, 970-988.	1.5	30
20	Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. <i>Journal of General Virology</i> , 2015, 96, 1478-1483.	1.3	10
21	A leader sequence capable of enhancing RNA expression and protein synthesis in mammalian cells. <i>Protein Science</i> , 2013, 22, 1392-1398.	3.1	11
22	Use of a Recombinant Vaccinia Virus Expressing Interferon Gamma for Post-Exposure Protection against Vaccinia and Ectromelia Viruses. <i>PLoS ONE</i> , 2013, 8, e77879.	1.1	7
23	The Amino Terminus of the Vaccinia Virus E3 Protein Is Necessary To Inhibit the Interferon Response. <i>Journal of Virology</i> , 2012, 86, 5895-5904.	1.5	37
24	In Vitro Characterization of a Nineteenth-Century Therapy for Smallpox. <i>PLoS ONE</i> , 2012, 7, e32610.	1.1	23
25	The NYCBH vaccinia virus deleted for the innate immune evasion gene, E3L, protects rabbits against lethal challenge by rabbitpox virus. <i>Vaccine</i> , 2011, 29, 7659-7669.	1.7	10
26	The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus. <i>Vaccine</i> , 2011, 29, 9691-9696.	1.7	7
27	Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques. <i>Vaccine</i> , 2011, 29, 9684-9690.	1.7	20
28	Use of a negative selectable marker for rapid selection of recombinant vaccinia virus. <i>BioTechniques</i> , 2011, 50, 303-309.	0.8	15
29	Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors. <i>PLoS ONE</i> , 2011, 6, e16819.	1.1	42
30	Improved NYVAC-Based Vaccine Vectors. <i>PLoS ONE</i> , 2011, 6, e25674.	1.1	59
31	Innate Immune Evasion Mediated by the <i>Ambystoma tigrinum</i> Virus Eukaryotic Translation Initiation Factor 2L± Homologue. <i>Journal of Virology</i> , 2011, 85, 5061-5069.	1.5	39
32	Evidence for Multiple Recent Host Species Shifts among the Ranaviruses (Family <i>Iridoviridae</i> ). <i>Journal of Virology</i> , 2010, 84, 2636-2647.	1.5	118
33	Protein Kinase PKR-Dependent Activation of Mitogen-Activated Protein Kinases Occurs through Mitochondrial Adapter IPS-1 and Is Antagonized by Vaccinia Virus E3L. <i>Journal of Virology</i> , 2009, 83, 5718-5725.	1.5	43
34	Vaccinia virus vaccines: Past, present and future. <i>Antiviral Research</i> , 2009, 84, 1-13.	1.9	211
35	Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Intra-nasal vaccination. <i>Vaccine</i> , 2008, 26, 664-676.	1.7	45
36	Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Scarification vaccination. <i>Vaccine</i> , 2008, 26, 2860-2872.	1.7	41

#	ARTICLE	IF	CITATIONS
37	Loss of Protein Kinase PKR Expression in Human HeLa Cells Complements the Vaccinia Virus E3L Deletion Mutant Phenotype by Restoration of Viral Protein Synthesis. <i>Journal of Virology</i> , 2008, 82, 840-848.	1.5	76
38	Inhibition of PKR by RNA and DNA viruses. <i>Virus Research</i> , 2006, 119, 100-110.	1.1	190
39	Suppression of Proinflammatory Signal Transduction and Gene Expression by the Dual Nucleic Acid Binding Domains of the Vaccinia Virus E3L Proteins. <i>Journal of Virology</i> , 2006, 80, 10083-10095.	1.5	70
40	Viral Countermeasures to the Host Interferon Response: Role of the Vaccinia Virus E3L and K3L Genes. , 2005, , 353-376.		0
41	The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. <i>Virology</i> , 2005, 333, 263-270.	1.1	53
42	Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L. <i>Virology</i> , 2004, 324, 419-429.	1.1	92
43	Inhibition of PKR by vaccinia virus: role of the N- and C-terminal domains of E3L. <i>Virology</i> , 2004, 324, 419-419.	1.1	0
44	Genomic sequence of a ranavirus (family Iridoviridae) associated with salamander mortalities in North America. <i>Virology</i> , 2003, 316, 90-103.	1.1	125
45	The Orf virus E3L homologue is able to complement deletion of the vaccinia virus E3L gene in vitro but not in vivo. <i>Virology</i> , 2003, 314, 305-314.	1.1	22
46	A role for Z-DNA binding in vaccinia virus pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6974-6979.	3.3	202
47	The Role of the PKR-Inhibitory Genes, E3L and K3L, in Determining Vaccinia Virus Host Range. <i>Virology</i> , 2002, 299, 133-141.	1.1	161
48	Vaccinia Virus E3L Interferon Resistance Protein Inhibits the Interferon-Induced Adenosine Deaminase A-to-I Editing Activity. <i>Virology</i> , 2001, 289, 378-387.	1.1	62
49	Both Carboxy- and Amino-Terminal Domains of the Vaccinia Virus Interferon Resistance Gene, E3L, Are Required for Pathogenesis in a Mouse Model. <i>Journal of Virology</i> , 2001, 75, 850-856.	1.5	191
50	Role of the Vaccinia Virus E3L and K3L Gene Products in Rescue of VSV and EMCV from the Effects of IFN- $\beta$ . <i>Journal of Interferon and Cytokine Research</i> , 1998, 18, 721-729.	0.5	44
51	Characterization of Viral Double-Stranded RNA-Binding Proteins. <i>Methods</i> , 1998, 15, 225-232.	1.9	14
52	Activation of Antiviral Protein Kinase Leads to Immunoglobulin E Class Switching in Human B Cells. <i>Journal of Virology</i> , 1998, 72, 1171-1176.	1.5	48
53	Complementation of Vaccinia Virus Deleted of the E3L Gene by Mutants of E3L. <i>Virology</i> , 1997, 239, 269-276.	1.1	64
54	Complementation of Deletion of the Vaccinia Virus E3L Gene by the Escherichia coli RNase III Gene. <i>Virology</i> , 1997, 227, 77-87.	1.1	28

#	ARTICLE	IF	CITATIONS
55	When Two Strands Are Better Than One: The Mediators and Modulators of the Cellular Responses to Double-Stranded RNA. <i>Virology</i> , 1996, 219, 339-349.	1.1	546
56	Host-range restriction of vaccinia virus E3L-specific deletion mutants. <i>Virus Genes</i> , 1996, 12, 89-94.	0.7	100
57	Site-Directed Mutagenic Analysis of Reovirus $\sigma 3$ Protein Binding to dsRNA. <i>Virology</i> , 1994, 204, 190-199.	1.1	61
58	Identification of a Conserved Motif That Is Necessary for Binding of the Vaccinia Virus E3L Gene Products to Double-Stranded RNA. <i>Virology</i> , 1993, 194, 537-547.	1.1	150
59	The mouse antiphosphotyrosine immunoreactive kinase, TIK, is indistinguishable from the double-stranded RNA-dependent, interferon-induced protein kinase, PKR. <i>Nucleic Acids Research</i> , 1993, 21, 4830-4835.	6.5	22
60	Atomic Force Microscopy Imaging of Double Stranded DNA and RNA. <i>Journal of Biomolecular Structure and Dynamics</i> , 1992, 10, 589-606.	2.0	161
61	Atomic force microscopy of reovirus dsRNA: a routine technique for length measurements. <i>Nucleic Acids Research</i> , 1992, 20, 3983-3986.	6.5	92
62	Characterization of a vaccinia virus-encoded double-stranded RNA-binding protein that may be involved in inhibition of the double-stranded rna-dependent protein kinase. <i>Virology</i> , 1991, 185, 206-216.	1.1	128
63	Histone Proteins Inhibit Activation of the Interferon-Induced Protein Kinase by Binding to Double-Stranded RNA. <i>Journal of Interferon Research</i> , 1988, 8, 821-830.	1.2	12